Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis

We report an unusual case of superior ophthalmic vein thrombosis, as the first manifestation of multiple myeloma. As far as we know, this is the first case described in the literature. Here we describe a patient presented with a painful, visual blur and a right-sided proptosis due to superior ophthalmic vein thrombosis. Appropriate medical workup was conducted, and smoldering multiple myeloma was diagnosed as the underlying cause. We further discuss the possible involved mechanisms.
Source: Saudi Journal of Ophthalmology - Category: Opthalmology Source Type: research

Related Links:

ConclusionThe results of this analysis emphasize the need for active management of patients with PV with appropriate HU dose titration to maintain blood count control while monitoring for signs and symptoms of HU intolerance.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Condition:   Venous Thromboembolism Intervention:   Drug: Apixaban 2.5 MG Sponsors:   Instituto de Investigacion Sanitaria La Fe;   Bristol-Myers Squibb Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
CONCLUSION: Thrombin generation appears to be higher in patients with myeloma compared with controls, especially in high-risk patients, and does not change significantly after treatment completion. PMID: 31421013 [PubMed - as supplied by publisher]
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Tags: Int J Lab Hematol Source Type: research
FRIDAY, Aug. 16, 2019 -- For patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), a risk assessment model, SAVED, can predict the risk for venous thromboembolism (VTE), according to a study published in the July issue of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
PNH and MPN are diseases associated with increased thrombosis. PNH clones are commonly found in other haematological diseases i.e. MDS and aplastic anemia. The presence of PNH clones was studied in consecutive MPN patients. A prevalence of 2% and an association with the JAK2 mutation was found. Presence of a PNH clone could potentially influence the clinical course of MPN.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Paroxysmal nocturnal hemoglobinuria (PNH) and myeloproliferative neoplasm (MPN) are diseases associated with increased thrombosis. PNH clones are commonly found in other hematologic diseases, such as myelodysplastic syndromes and aplastic anemia. The presence of PNH clones was studied in consecutive MPN patients. A prevalence of 2% and an association with the JAK2 mutation was found. Presence of a PNH clone could potentially influence the clinical course of MPN.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
WEDNESDAY, Aug. 7, 2019 -- A new risk prediction score outperforms current guidelines for predicting venous thromboembolism (VTE) in multiple myeloma (MM), according to a study published online Aug. 4 in the American Journal of Hematology. Kristen...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
This study aimed to derive and validate a new risk assessment model (RAM) for IMiD-associated VTE. METHODS: Patients with newly diagnosed MM receiving IMiDs were selected from the SEER-Medicare database (n=2,397) to derive a RAM and then data from the Veterans Health Administration database (n=1,251) were used to externally validate the model. A multivariable cause-specific Cox regression model was used for model development. RESULTS: The final RAM, named the "SAVED" score, included 5 clinical variables: prior surgery, Asian race, VTE history, age ≥80 years, and dexamethasone dose. The model stratified...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
We describe a 40-year-old woman who presented with lower cranial neuropathies mimicking variant Guillain-Barré syndrome, with normal brain and spinal cord imaging and cerebrospinal fluid (CSF) albuminocytological dissociation, and subsequently diagnosed with IgD myeloma. She relapsed repeatedly with differing neurological presentations: numb chin syndrome and twice with impaired vision, first from cerebral venous sinus thrombosis and later from leptomeningeal infiltration of the optic chiasm. We discuss the neurological complications of myeloma, emphasising the need to consider it in a wide variety of neurological p...
Source: Practical Neurology - Category: Neurology Authors: Tags: Pract Neurol Source Type: research
More News: Middle East Health | Myeloma | Opthalmology | Pathology | Saudi Arabia Health | Thrombosis